Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Next Previous
Search
Trial Profile

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-1
  • Sponsors Amgen; Bausch Health Companies

    • Most Recent Events

    • 01 Feb 2022 Results assessing efficacy of brodalumab in patients with nail or scalp psoriasis in three phase 3 studies (AMAGINE-1/-2/-3), published in the Journal of Dermatological Treatment.
    • 01 Oct 2021 Results of post-hoc analysis of two phase 3 studies (AMAGINE-1 &2) patients achieving complete clearance and the cumulative clinical benefit of treatment with brodalumab vs. ustekinumab over a 52-week period in the AMAGINE-2 and AMAGINE-3 trials according to prior treatment with systemic medications and/or biologic agents, published in the Journal of the European Academy of Dermatology and Venereology.
    • 25 Apr 2021 Results of pooled post hoc analysis from AMAGINE 1, 2 and 3; examining PASI component scores of patients with psoriasis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top